Status of Patients With Asymptomatic Cardiac Involvement at Baseline
| Patient . | Age*/Gender . | Months Since Therapy . | PS . | Response . | Baseline LVTM (cm) . | Follow-up LVTM (cm) . |
|---|---|---|---|---|---|---|
| 2 | 42M | 38 | 0 | CR | 1.2 | 1.2 |
| 4 | 39M | 36 | 0 | CR | 1.4 | 1.0 |
| 8 | 42W | 30 | 0 | CR | 0.9 | 0.7 |
| 9 | 45M | 29 | 1 | PD | 1.2 | 1.2 |
| 13 | 29W | 24 | 0 | CR | 0.7 | 1.0 |
| 17 | 31W | 19 | 0 | CR | 1.2 | 1.0 |
| 22 | 56W | 14 | 0 | CR | 1.5 | NA |
| 23 | 37W | 13 | 2 | PD | 0.9 | 1.2 |
| Patient . | Age*/Gender . | Months Since Therapy . | PS . | Response . | Baseline LVTM (cm) . | Follow-up LVTM (cm) . |
|---|---|---|---|---|---|---|
| 2 | 42M | 38 | 0 | CR | 1.2 | 1.2 |
| 4 | 39M | 36 | 0 | CR | 1.4 | 1.0 |
| 8 | 42W | 30 | 0 | CR | 0.9 | 0.7 |
| 9 | 45M | 29 | 1 | PD | 1.2 | 1.2 |
| 13 | 29W | 24 | 0 | CR | 0.7 | 1.0 |
| 17 | 31W | 19 | 0 | CR | 1.2 | 1.0 |
| 22 | 56W | 14 | 0 | CR | 1.5 | NA |
| 23 | 37W | 13 | 2 | PD | 0.9 | 1.2 |
These patients had asymptomatic amyloid cardiac involvement at baseline before dose-intensive melphalan therapy. Their predominant organs of involvement were not cardiac (see Table 2). Complete hematologic responses after therapy have been associated with improved functional status and, in two instances (patients 4 and 17), with reductions in the average thickness of the left ventricle by echocardiogram.
Abbreviations: PS, performance status; LVTM, mean left ventricular wall thickness (average of posterior and septal walls); CR, complete hematologic response; PD, persistent plasma cell disease.
Age at treatment.